��è��Ƶ

Skip to content

New Scientist. Science news and long reads from expert journalists, covering developments in science, technology, health and the environment on the website and the magazine.

Theme park visitors show their covid passes in France, July 2021

Health

Covid-19: What can we expect from the pandemic in 2022?

In the third year of the coronavirus pandemic, expect more variants, lower death rates and some continuing restrictions

��è��Ƶ

Covid-19 news archive: November to December 2021

Health

Covid-19 news archive: November to December 2021

��è��Ƶ

A new hospital was rapidly built in Wuhan, China, in early 2020

Health

Two years of covid-19: What we’ve learned during the pandemic so far

��è��Ƶ

SARS-CoV-2 Delta variant. Coloured scanning electron micrograph (SEM). Here the delta variant is shown budding (cyan dots) from an apoptotic Caco-2 human gut epithelial cell 24 hours after infection. SARS-CoV-2 Delta variant took over globally from the alpha variant in 2021. The delta variant has evolved to better replicate in its new human host allowing it to spread between people more efficiently. The coronaviruses take their name from their crown (corona) of surface proteins, which are used to attach and penetrate their host cells. As of mid-September 2021 226, 130, 821 cases and 4, 653, 230 deaths have been recorded world- wide. Magnification x 8000 at 10cm wide. Specimen courtesy of Greg Towers, UCL

Health

2022 preview: What will the coronavirus do next?

��è��Ƶ

A technician uses a multi-channel pipette dropper to dispense liquid material inside the Afrigen Biologics & Vaccines Ltd. laboratory facility in Cape Town, South Africa, on Monday, July 12, 2021. The??World Health Organization announced it will establish its first-ever mRNA technology transfer hub in Cape Town in an agreement with??Afrigen??and the??Biovac Institute. Photographer: Dwayne Senior/Bloomberg via Getty Images

Health

��è��Ƶ's predictions for the big science stories of 2022

Leader

FILE -- Henry Magendantz, a participant in the Aduhelm clinical trial, finishes receiving an infusion of the drug at Butler Hospital in Providence, R.I., May 27, 2021. Two months before the Food and Drug Administration's deadline to decide whether to approve Biogen's controversial Alzheimer's drug aducanumab, a council of senior agency officials resoundingly agreed that there wasn't enough evidence it worked. (Kayana Szymczak/The New York Times) / Redux / eyevine Please agree fees before use. SPECIAL RATES MAY APPLY. For further information please contact eyevine tel: +44 (0) 20 8709 8709 e-mail: info@eyevine.com www.eyevine.com

Health

2022 preview: Expect a row over controversial Alzheimer's drug

��è��Ƶ

MARBURG, GERMANY - MARCH 29: Employees in special suits test the procedures for the manufacturing of the messenger RNA (mRNA) for the Covid-19 vaccine in German company BioNTech, in Marburg, Germany on March 29, 2021. BioNTech Marburg's coronavirus vaccine production target will be 2.5 billion doses for 2021, up from 2.3 billion as it is considered as one of the largest manufacturing facilities producing mRNA vaccines in the world. The Pfizer-BioNTech vaccine was developed by Ozlem Tureci and Ugur Sahin, a couple who are children of Turkish immigrants in Germany. (Photo by Abdulhamid Hosbas/Anadolu Agency via Getty Images)

Health

2022 preview: mRNA tech behind covid-19 vaccines could get new uses

��è��Ƶ

How shifting your expectations about food can help you lose weight

Health

How shifting your expectations about food can help you lose weight

Features

Prescriptions of pills that can be taken at home could help prevent people developing severe covid-19

Health

UK has begun using drugs for covid-19 cases before they become severe

��è��Ƶ

Circuit Board With Encoder And Decoder Binary Code Vector Background. Blue Abstract Brain Security Technology Illustration.

Health

Florian Solzbacher interview: Mind-reading implant may soon go on sale

The president of Blackrock Neurotech says the company’s brain-computer interface, designed for people who are paralysed, could be available in 2022 if regulators approve it

��è��Ƶ

Health

Why the UK’s booster campaign mustn’t forget the vaccine hesitant

Analysis

Health

The year of coronavirus variants: How evolution tormented us in 2021

��è��Ƶ

Health

Cuba’s home-grown vaccines have massively cut covid-19 cases

��è��Ƶ

Health

Covid-19 was the third leading cause of death in the US in 2020

��è��Ƶ